Cytochrome P450 2C19 genotyping for personalisation of proton pump inhibitor therapy

Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/107950

Title:	Cytochrome P450 2C19 genotyping for personalisation of proton pump inhibitor therapy
Authors:	DeBattista, J. L. Schembri, J. Barbara, Christopher Zahra, Graziella Wirth, Francesca Azzopardi, Lilian M.
Keywords:	Proton pump inhibitors -- Therapeutic use Cytochrome P-450 CYP2C19 Inhibitors Pharmacist and patient Pharmacy -- Practice
Issue Date:	2023-03
Publisher:	University of Malta. Department of Pharmacy
Citation:	Debattista, J. L., Schembri, J., Barbara, C., Zahra, G., Wirth, F., & Azzopardi, L.M. (2023, March). Cytochrome P450 2C19 genotyping for personalisation of proton pump inhibitor therapy. Poster session presented at the 27th Annual Congress of the European Association of Hospital Pharmacists (EAHP), Lisbon, Portugal.
Abstract:	BACKGROUND AND IMPORTANCE: Proton pump inhibitors (PPIs) are the main class of drugs used in clinical practice for acid suppression to treat and prevent various conditions, including gastro oesophageal reflux disease (GORD) and peptic ulcer disease (PUD). PPIs are generally considered effective, however sub optimal response has been reported. PPIs are hepatically metabolised, primarily by the polymorphic cytochrome P (CYP) 450 2C19 enzyme. CYP2C19 genetic polymorphisms have been associated with affecting exposure and efficacy of PPIs. AIM: To determine the prevalence and clinical implications of CYP2C19 genetic polymorphisms in patients receiving PPIs and demonstrating therapy resistance.
URI:	https://www.um.edu.mt/library/oar/handle/123456789/107950
Appears in Collections:	Scholarly Works - FacM&SPha

Files in This Item:

File	Description	Size	Format
Cytochrome P450 2C19 genotyping for personalisation of proton pump inhibitor therapy 2023.pdf		308.03 kB	Adobe PDF	View/Open

Show full item record Statistics